{"entity":{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","aka":[],"tldr":"A breast and gynaecologic oncologist deeply involved in the early trastuzumab deruxtecan studies and in Japanese ADC development.","summary":"Kan Yonemori is Chief of the Department of Medical Oncology at the National Cancer Center Hospital in Tokyo. A breast and gynaecologic oncologist, he was deeply involved in the early studies of trastuzumab deruxtecan and in Japanese antibody-drug conjugate development, serving as an investigator on the DESTINY-Breast trials. His publications include the phase 1 dose-escalation study of trastuzumab deruxtecan in advanced breast and gastric tumours, a phase 1/2 trial of the HER3-directed conjugate patritumab deruxtecan in metastatic breast cancer, and the long-term analysis of DESTINY-Breast03 comparing trastuzumab deruxtecan with trastuzumab emtansine. He leads medical oncology across breast, gynaecologic and sarcoma indications.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yonemori%20K%5BAuthor%5D%20National%20Cancer%20Center"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","ovarian"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Department of Medical Oncology, National Cancer Center Hospital","institutionId":"ncc-japan","specialisms":["Breast cancer","Antibody-drug conjugates","Gynaecologic oncology","Sarcoma"],"profiles":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yonemori%20K%5BAuthor%5D%20National%20Cancer%20Center"}],"papers":[{"title":"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.23.00882"},{"title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30604-6"},{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","journal":"Nature Medicine","year":2024,"doi":"10.1038/s41591-024-03021-7"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"}]},"route":"/people/yonemori-kan/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/"}],"paper":[{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/"}]}}